{"name":"LXR Biotechnology","slug":"lxr-biotechnology","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQX1dfSFBFWUwtT0lOZF9uV0w5MlFfQmVhSW9adnRnaktyUzZZUTVJeTdzZzNPZ1puR0hZWk1WYnVWRVM0MTlPOE9pOTBCX1BES0FzYlpoSE93MUZqSi05dV9HV3haWU53OUJBVXcxdVJpc2hqNU5DM213RlNudmlkRlREeTFsOC13M2Y1cVl4cXlVb2JfZkNZUXhodm1WdnFKaFZRNlV5MTBfVGd4T0ZCUEw2SkY?oc=5","date":"2026-02-10","type":"trial","source":"Fierce Biotech","summary":"OrsoBio hits target in midstage study for metabolic conditions but stays silent on details - Fierce Biotech","headline":"OrsoBio hits target in midstage study for metabolic conditions but stays silent on details","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNLVpkVFo4X3d0Vk8tSGpDNERyc25fT0NFbngyczlpN0I5eExVZjZVMDB1d082VHNTTWZwdF9tam1DeUl1aGIwNktRQVNuczRWQ29JdGVnQ29saUx3VVZqejA4TUlidnplZlVpUThJMHg1ZzRpcDBDa2FRWXBPQm1yZEwtUlVtM2xoQnJrR05YckN0LU5Eb2cxbC1XNGJwS0htQmZoVm5YMDZqcjZIX1BqTGpsbi1VMGdTMnhVb2JlXzNiN1N3TTdDMGFyeUVSWFk?oc=5","date":"2025-06-11","type":"pipeline","source":"PR Newswire","summary":"Specific Biologics Welcomes Paul J. Hastings as Chair of the Board of Directors - PR Newswire","headline":"Specific Biologics Welcomes Paul J. Hastings as Chair of the Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOeTFIY0NDOWY2T3hDWWt3RHV6bXdzbXlSMUszQ3ZqendBeF9iZ3BNanBLMVZpYl90aG1iZFFpYkU5cEw0eVoyMWJ3bjVTQm5TQWg4U0E4dmZ5ZWotVzZ4NjBQcGpMVGxUQ0s1eWNNN2RCWmdRUUxtWUFGTVhfLV9QMkE2S1hIUmVzcGZxb0htVjU0ZGwwa3kyNnlwa2E1TWZrSlZwS1F4QTY?oc=5","date":"2025-04-01","type":"pipeline","source":"Fierce Biotech","summary":"Cancer biotech Inspirna winding down as its odyssey in microRNA comes to an end - Fierce Biotech","headline":"Cancer biotech Inspirna winding down as its odyssey in microRNA comes to an end","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFAxVG1aWkFXZVhGM1FBMWxUbl9iajRfb2hXaEFtSi1JWFRCVlhOZXNzMVdZRUpQbkd3MmNyQ2ZkUjByOEM2ZG9DQkdsWkxnT0p0MGY4VmFsd0FEMkQtbm9oQW9ScjdjVlQxNlhzZ2trQVFmdw?oc=5","date":"2023-11-16","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Digital trends shaping pharma and biotech industries in 2023 - drugdiscoverytrends.com","headline":"Digital trends shaping pharma and biotech industries in 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5DdzZUMjl0Sk1ROG01dGdPOUFCUkJiV3h0cmwtWHF3YVhDMVhySmpWSV9WQkVjM1hXTU5PdVJDVmJZT3gyUWxSY055d2ZueFUwZjM4SW1GWk1JTXctcFJZQTBMRmRPMFRp?oc=5","date":"2021-09-16","type":"pipeline","source":"Science | AAAS","summary":"On the Biotech Pharm, a Race to Harvest New Cancer Cures - Science | AAAS","headline":"On the Biotech Pharm, a Race to Harvest New Cancer Cures - Science | AAAS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNVGdtRW9sNncwMW1pbmljbGo2UnRkcUFuSEt6Q0JLdm8wN2VMajNKUm5uWmJaSExMbG9TV29iMkRXM1JjVjNTR0VRV2l2Ty1YUTVrQkNwWjZoYWp6VVNZYmpHUXRDWXc0VWU1b2tMVVNCOXJpaUFrUTdsU2trbVJtVTBtSnROUndtSDF6Qk5iLXh0NGN2dVBZVQ?oc=5","date":"2019-09-16","type":"pipeline","source":"Fierce Biotech","summary":"Foghorn and Rgenix nab Agios, Roche veterans as new CMOs - Fierce Biotech","headline":"Foghorn and Rgenix nab Agios, Roche veterans as new CMOs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQUzlKSlduUEJKUXNBb2taYmR0THlUQUlsM2tCQUFTMUJlY2xtWGZGczNWMlVKcHNFY21RWENfVUJEbVJBNC1JWVNBaFpwMDlrNTZ1dWhGYkhRRFZ1TzI5QWdRM1ZOMWJRNGNZdWNWdTBuZVY5TnVXT1Rmd3djZ25sbW1RVjNIS0J4Mlg5S2FVTjVkSU8yRlBXZGdxNllab3M?oc=5","date":"2017-04-27","type":"trial","source":"Fierce Biotech","summary":"Rgenix hires ex-Novartis cancer staffer to trial GSK castoff - Fierce Biotech","headline":"Rgenix hires ex-Novartis cancer staffer to trial GSK castoff","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPNHNDOUd6LUdVZ0ZXUkJscmx5OWhpWE1Fd3BhUVczMEs0Sjg0N1MxQS1pVW9JdS1BMGZxYmdmSHpoSjdOOWtkQ1NzaVdHUldINm1OQ0V1X0IyN0NPRXdiQ2pZR2VKU3Zxa1NjdmI4WE9YMnhWWWJMLUhlYTdXY0gydWRZY1ZQWXExYkxnTms2UVVxV1c5d3BEYk1lX3FoLTNSRlV3?oc=5","date":"2016-06-29","type":"pipeline","source":"BioPharma Dive","summary":"What does it take to succeed as a New York biotech startup? - BioPharma Dive","headline":"What does it take to succeed as a New York biotech startup?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPSWVnY0FKdTR5bVhYMnRwNjdTdGtwT1dUbDdzLW11emptTjFFZ0VSUDNjalNfc1FWaGkyS3l1dkhFWDdsT1ZuX0NuTkRUcGxfUWRteHo1M29GMGtmNFREY3FJVURtMkZqSEJHWkhjODBEXzlBYllROUREUmZTM0FPSmQtMzdRbmF4ZTY0cmVtUlY0UQ?oc=5","date":"2014-10-22","type":"pipeline","source":"The University of Rhode Island","summary":"URI to present Distinguished Achievement Awards, Oct. 25 – Rhody Today - The University of Rhode Island","headline":"URI to present Distinguished Achievement Awards, Oct. 25 – Rhody Today","sentiment":"neutral"},{"date":"1999-12-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"1999-11-24","type":"earnings","source":"SEC EDGAR","summary":"SC 13D filed with SEC","headline":"SC 13D Filing","sentiment":"neutral"},{"date":"1999-11-15","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: LXR BIOTECHNOLOGY INC FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"1999-08-16","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q DATED JUNE 30, 1999","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"1999-06-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K DATED JUNE 10, 1999","headline":"SEC 8-K: FORM 8-K DATED JUNE 10, 1999","sentiment":"neutral"},{"date":"1999-05-17","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: LXR BIOTECHNOLOGY INC FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}